MedTrace Logo

Enhancement of Macular Pigment Density by Oral Lutein Supplementation

NCT00563979 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-06-12

No results posted yet for this study

Summary

The primary objective of EMPOLS is an increase in macular pigment density (MPD) and contrast sensitivity (CS) after six months supplementation of oral non-compound ester Lutein 10 mg daily, contained in VitaluxPlus®.

Conditions

  • Age-Related Maculopathies

Interventions

DIETARY_SUPPLEMENT

VitaluxPlus®

1 tablet daily

DIETARY_SUPPLEMENT

Omega 3

1 tablet daily

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Sebastian Wolf, MD · University of Bern

  • Ute Wolf-Schnurrbusch, MD · University of Bern

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00563979 on ClinicalTrials.gov